08:00 , Mar 8, 2004 |  BioCentury  |  Finance

Ebb & Flow

With two months of the year already gone, the trends are saying that the IPO window is helping to open venture purse strings. In the U.S., private companies raised $641 million to the end of...
07:00 , Oct 8, 2001 |  BioCentury  |  Finance

Ebb & Flow

Whether it's a dead-cat bounce or the start of a rally, biotech has posted the best performance of the major indexes tracked by BioCentury over the past two weeks. Since Sept. 21 - the Friday...
07:00 , Oct 3, 2001 |  BC Extra  |  Financial News

Big biotech venture rounds

Three biotech venture financings of at least $20 million closed on Wednesday. Altus ( Cambridge , Mass.) raised $35 million in a private financing with Nomura International; U.S. Venture Partners; BankInvest; Clariden Bank; and other...
07:00 , Jul 23, 2001 |  BC Week In Review  |  Company News

Gene Logic genomics news

GLGC spun out its Flow-thru-Chip technology into a company called MetriGenix Inc. MetriGenix will market the Flow-thru-Chip biomolecular analysis platform and its associated instrumentation and software as a multigene screening tool. The new company has...
07:00 , Jul 23, 2001 |  BioCentury  |  Finance

Ebb & Flow

The venture crowd did more than their fair share of the financing work last week, with eight private equity deals accounting for $100.4 million (63%) of the $159.4 million raised. Only two public deals completed...
07:00 , Jul 23, 2001 |  BioCentury  |  Finance

Ebb & Flow

The venture crowd did more than their fair share of the financing work last week, with eight private equity deals accounting for $100.4 million (63%) of the $159.4 million raised. Only two public deals completed...
07:00 , Jul 19, 2001 |  BC Extra  |  Company News

Gene Logic spins out technology

GLGC spun out its Flow-thru-Chip technology into a company called MetriGenix . MetriGenix will market the Flow-thru-Chip biomolecular analysis platform and its associated instrumentation and software as a multigene screening tool. The new company has...
07:00 , Oct 23, 2000 |  BioCentury  |  Finance

Mutual respect for biotech

Although biotech stocks have taken a drubbing so far this quarter, fund managers do not appear to be getting out of the group or increasing the percentage of cash holdings in their funds. Nor does...
07:00 , Oct 16, 2000 |  BC Extra  |  Financial News

Cellomics raises $30 million

Cell-based drug discovery company Cellomics (Pittsburgh, Penn.) raised $30 million in a private round. Investors included Amerindo Investment Advisors; INVESCO; Alta Partners; Burrill Biotechnology Capital Fund; BayStar Capital; Ariane Health Fund; LCF Rothschild; Biosphere; InterWest...
07:00 , Aug 7, 2000 |  BioCentury  |  Finance

Springloaded in Europe

While investors in NASDAQ-listed biotech IPOs have made quick paper gains, European biotech flotations are also providing investors with an opportunity to make a quick profit. Of the 11 European IPOs that have priced since...